{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:59:05Z","timestamp":1781643545897,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["PQ fellowships"],"award-info":[{"award-number":["PQ fellowships"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004916","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Amazonas","doi-asserted-by":"publisher","award":["Pr\u00f3-Estado Program \u2014 No. 002\/2008, FAPEAM Grants No. 007\/2018 and No. 005\/2019; POSGRAD \u2014 No. 002\/2024"],"award-info":[{"award-number":["Pr\u00f3-Estado Program \u2014 No. 002\/2008, FAPEAM Grants No. 007\/2018 and No. 005\/2019; POSGRAD \u2014 No. 002\/2024"]}],"id":[{"id":"10.13039\/501100004916","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the t(9;22)(q34;q11.2) translocation, known as the Philadelphia chromosome (Ph+), which generates the\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      fusion oncogene central to CML pathogenesis. The disease accounts for approximately 15% of adult leukemias, predominantly affects males, and has a median age at diagnosis of around 57 years. CML typically presents in the chronic phase and may progress to advanced disease phases, with prognostic risk stratification guiding treatment decisions. Tyrosine kinase inhibitors (TKIs) are the cornerstone of therapy, aiming to achieve durable molecular disease control and, in selected patients, sustained deep molecular response and treatment-free remission. This study evaluated the demographic, clinical, and molecular response profiles of patients with Ph\u2009+\u2009CML treated with first- and second-line TKIs at the Funda\u00e7\u00e3o Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective, longitudinal study analyzed medical records of 176 patients diagnosed with Ph\u2009+\u2009CML between 2011 and 2020. Demographic characteristics, clinical data, and laboratory findings were extracted from medical records. Longitudinal molecular response was assessed in patients with available\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      monitoring.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 176 patients identified, 122 were included in the analysis of treatment outcomes. The mean age at diagnosis was 49.6 years, with a slight male predominance. Most patients were diagnosed in the chronic phase, and high-risk Sokal score was the most frequent prognostic category among evaluable cases. The e14a2 (b3a2) transcript was the most prevalent molecular subtype. Clinically meaningful molecular responses were observed in both first- and second-line treatment settings, although response assessment was influenced by real-world constraints, including incomplete molecular monitoring and heterogeneous follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings provide real-world insights into the epidemiological, clinical, and molecular response characteristics of Ph\u2009+\u2009CML patients treated in the Amazon region. The study highlights the challenges of implementing guideline-based molecular monitoring in geographically constrained settings and supports the need for adapted strategies to optimize long-term CML management in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15843-4","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:14:23Z","timestamp":1774401263000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-life data of patients with chronic myeloid leukemia in Amazonas"],"prefix":"10.1186","volume":"26","author":[{"given":"Ros\u00e2ngela Santos","family":"Abreu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasthyhellen Souto","family":"Maior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iandara Maira Lopes","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5639-7041","authenticated-orcid":false,"given":"Jhemerson Fernandes","family":"Paes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Eduardo Feitosa","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaella Oliveira","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja Pinto Garcia","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia Pereira","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7312-6822","authenticated-orcid":false,"given":"Allyson Guimar\u00e3es","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1107-8079","authenticated-orcid":false,"given":"Adriana","family":"Malheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5494-4889","authenticated-orcid":false,"given":"Olindo Assis","family":"Martins-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3125-580X","authenticated-orcid":false,"given":"Andr\u00e9a Monteiro","family":"Tarrag\u00f4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8518-8564","authenticated-orcid":false,"given":"Leny Nascimento Motta","family":"Passos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"15843_CR1","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","volume":"129","author":"TL Holyoake","year":"2017","unstructured":"Holyoake TL, Vetrie D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood. 2017;129:1595\u2013606. https:\/\/doi.org\/10.1182\/blood-2016-09-696013.","journal-title":"Blood"},{"key":"15843_CR2","volume-title":"Myeloproliferative neoplasms. StatPearls [Internet]","author":"B Thapa","year":"2023","unstructured":"Thapa B, Fazal S, Parsi M, Rogers HJ. Myeloproliferative neoplasms. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023."},{"key":"15843_CR3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s11899-019-00546-4","volume":"14","author":"F Rabian","year":"2019","unstructured":"Rabian F, Lengline E, Rea D. Towards a personalized treatment of patients with chronic myeloid leukemia. Curr Hematol Malig Rep. 2019;14:492\u2013500. https:\/\/doi.org\/10.1007\/s11899-019-00546-4.","journal-title":"Curr Hematol Malig Rep"},{"key":"15843_CR4","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ajh.26642","volume":"97","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol. 2022;97:1236\u201356. https:\/\/doi.org\/10.1002\/ajh.26642.","journal-title":"Am J Hematol"},{"key":"15843_CR5","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/leu.2015.73","volume":"29","author":"VS Hoffmann","year":"2015","unstructured":"Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries. Leukemia. 2015;29:1336\u201343. https:\/\/doi.org\/10.1038\/leu.2015.73.","journal-title":"Leukemia"},{"key":"15843_CR6","doi-asserted-by":"publisher","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","volume":"28","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, et al. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv41\u201351. https:\/\/doi.org\/10.1093\/annonc\/mdx219.","journal-title":"Ann Oncol"},{"key":"15843_CR7","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.3390\/jcm9113671","volume":"9","author":"R Hehlmann","year":"2020","unstructured":"Hehlmann R. The new ELN recommendations for treating CML. J Clin Med. 2020;9:3671. https:\/\/doi.org\/10.3390\/jcm9113671.","journal-title":"J Clin Med"},{"key":"15843_CR8","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.7150\/jca.29528","volume":"10","author":"HQ Zhu","year":"2019","unstructured":"Zhu HQ, Gao FH. Regulatory molecules and corresponding processes of BCR-ABL protein degradation. J Cancer. 2019;10:2488\u2013500. https:\/\/doi.org\/10.7150\/jca.29528.","journal-title":"J Cancer"},{"key":"15843_CR9","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1515\/med-2021-0309","volume":"16","author":"H Amin","year":"2021","unstructured":"Amin H, Ahmed S. Characteristics of BCR-ABL gene variants in patients with chronic myeloid leukemia. Open Med (Wars). 2021;16:904\u201312. https:\/\/doi.org\/10.1515\/med-2021-0309.","journal-title":"Open Med (Wars)"},{"key":"15843_CR10","doi-asserted-by":"publisher","unstructured":"Funke VM, Bitencourt H, Vigorito AC, Aranha FJ. Leucemia mieloide cr\u00f4nica e outras doen\u00e7as mieloproliferativas. Rev Bras Hematol Hemoter. 2010;32(Suppl 1):8\u201313. https:\/\/doi.org\/10.1590\/S1516-84842010005000045.","DOI":"10.1590\/S1516-84842010005000045"},{"key":"15843_CR11","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1269\/jrr.30.352","volume":"30","author":"K Tanaka","year":"1989","unstructured":"Tanaka K, Takechi M, Hong J, Shigeta C, Oguma N, Kamada N, et al. t(9;22) translocation and bcr rearrangements in chronic myelocytic leukemia patients among atomic bomb survivors. J Radiat Res. 1989;30:352\u20138. https:\/\/doi.org\/10.1269\/jrr.30.352.","journal-title":"J Radiat Res"},{"key":"15843_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4274\/tjh.galenos.2019.2019.0241","volume":"37","author":"IC Haznedaroglu","year":"2020","unstructured":"Haznedaroglu IC, Kuzu I, Ilhan O. WHO 2016 definition of chronic myeloid leukemia and tyrosine kinase inhibitors. Turk J Hematol. 2020;37:42\u20137. https:\/\/doi.org\/10.4274\/tjh.galenos.2019.2019.0241.","journal-title":"Turk J Hematol"},{"key":"15843_CR13","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.1016\/S2152-2650(21)01244-1","volume":"21","author":"A Hochhaus","year":"2021","unstructured":"Hochhaus A. State of the art in CML: update. Clin Lymphoma Myeloma Leuk. 2021;21:S151\u20132. https:\/\/doi.org\/10.1016\/S2152-2650(21)01244-1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"15843_CR14","doi-asserted-by":"publisher","first-page":"100825","DOI":"10.1016\/j.blre.2021.100825","volume":"49","author":"AEG Osman","year":"2021","unstructured":"Osman AEG, Deininger MW. Chronic myeloid leukemia: modern therapies, current challenges and future directions. Blood Rev. 2021;49:100825. https:\/\/doi.org\/10.1016\/j.blre.2021.100825.","journal-title":"Blood Rev"},{"key":"15843_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1365-2141.2011.08603.x","volume":"153","author":"L Foroni","year":"2011","unstructured":"Foroni L, Wilson G, Gerrard G, Mason J, Grimwade D, White HE, et al. Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia. Br J Haematol. 2011;153:179\u201390. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08603.x.","journal-title":"Br J Haematol"},{"key":"15843_CR16","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384. https:\/\/doi.org\/10.1038\/s41375-020-0776-2.","journal-title":"Leukemia"},{"key":"15843_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-022-01309-0","volume":"15","author":"V Garcia-Gutierrez","year":"2022","unstructured":"Garcia-Gutierrez V, Breccia M, Jabbour E, Mauro M, Cortes JE. A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. J Hematol Oncol. 2022;15:90. https:\/\/doi.org\/10.1186\/s13045-022-01309-0.","journal-title":"J Hematol Oncol"},{"key":"15843_CR18","volume-title":"Relatorio de recomendacao: protocolos clinicos e diretrizes terapeuticas - leucemia mieloide cronica do adulto","author":"Ministerio da Saude (BR)","year":"2021","unstructured":"Ministerio da Saude (BR). Relatorio de recomendacao: protocolos clinicos e diretrizes terapeuticas - leucemia mieloide cronica do adulto. Brasilia: CONITEC; 2021."},{"key":"15843_CR19","doi-asserted-by":"publisher","first-page":"e356","DOI":"10.1097\/HS9.0000000000000356","volume":"3","author":"F Castagnetti","year":"2019","unstructured":"Castagnetti F, Gugliotta G, Soverini S, Baccarani M, Rosti G. Current treatment approaches in CML. HemaSphere. 2019;3:e356. https:\/\/doi.org\/10.1097\/HS9.0000000000000356.","journal-title":"HemaSphere"},{"key":"15843_CR20","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.5045\/br.2023.2023035","volume":"58","author":"JJ Han","year":"2023","unstructured":"Han JJ. Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia. Blood Res. 2023;58:S58\u201365. https:\/\/doi.org\/10.5045\/br.2023.2023035.","journal-title":"Blood Res"},{"key":"15843_CR21","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020;37:530\u201342. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.006.","journal-title":"Cancer Cell"},{"key":"15843_CR22","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.htct.2018.08.009","volume":"41","author":"WBD Neves","year":"2019","unstructured":"Neves WBD, Brito AM, Vasconcelos AP, Melo FCBC, Melo RAM. Incidence and spatial distribution of chronic myeloid leukemia by regions of economic development in the state of Pernambuco, Brazil. Hematol Transfus Cell Ther. 2019;41:212\u20135. https:\/\/doi.org\/10.1016\/j.htct.2018.08.009.","journal-title":"Hematol Transfus Cell Ther"},{"key":"15843_CR23","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.htct.2020.10.219","volume":"42","author":"GSL Neto","year":"2020","unstructured":"Neto GSL, Gomes CV, Nunes DV, Aguilar LB, Montenegro LHF, Galvao ND, et al. Epidemiological profile of chronic myeloid leukemia cases in the two largest cities of Mato Grosso, Brazil, 2000\u20132016. Hematol Transfus Cell Ther. 2020;42:130. https:\/\/doi.org\/10.1016\/j.htct.2020.10.219.","journal-title":"Hematol Transfus Cell Ther"},{"key":"15843_CR24","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1007\/s00277-023-05189-3","volume":"102","author":"A Pifano","year":"2023","unstructured":"Pifano A, Ferreira S, Seguro FS, Ramires A, Abdo N, et al. Real-world imatinib mesylate treatment in patients with chronic myeloid leukemia: the importance of molecular monitoring and early molecular response. Ann Hematol. 2023;102:1761\u201371. https:\/\/doi.org\/10.1007\/s00277-023-05189-3.","journal-title":"Ann Hematol"},{"key":"15843_CR25","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","volume":"114","author":"M Deininger","year":"2009","unstructured":"Deininger M, O\u2019Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression in patients with newly diagnosed chronic-phase CML treated with imatinib. Blood. 2009;114:1126. https:\/\/doi.org\/10.1182\/blood.V114.22.1126.1126.","journal-title":"Blood"},{"key":"15843_CR26","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","volume":"95","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95:691\u2013709. https:\/\/doi.org\/10.1002\/ajh.25792.","journal-title":"Am J Hematol"},{"key":"15843_CR27","doi-asserted-by":"publisher","first-page":"e6992","DOI":"10.56083\/RCV4N12-170","volume":"4","author":"MO Nascimento","year":"2024","unstructured":"Nascimento MO, Marques VCR, Nascimento BEF, Cordeiro JSM, Sampaio VS, Santos RO, et al. Distribuicao da leucemia mieloide cronica na populacao amazonense. Rev Contemp. 2024;4:e6992. https:\/\/doi.org\/10.56083\/RCV4N12-170.","journal-title":"Rev Contemp"},{"key":"15843_CR28","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.1003082","volume-title":"Amazon ecosystem \u2013 past discoveries and future prospects","author":"J Emerson Souza","year":"2023","unstructured":"Emerson Souza J, Almeida Costa C, Peixoto Franca G, Alonso N. Difficulties in accessing medical surgical care in the Amazonas. Amazon ecosystem \u2013 past discoveries and future prospects. London: IntechOpen; 2023. https:\/\/doi.org\/10.5772\/intechopen.1003082."},{"key":"15843_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","volume":"8","author":"T Barbui","year":"2018","unstructured":"Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8:15. https:\/\/doi.org\/10.1038\/s41408-018-0054-y.","journal-title":"Blood Cancer J"},{"key":"15843_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3906\/sag-1810-81","volume":"49","author":"E Aladag","year":"2019","unstructured":"Aladag E, Haznedaroglu IC. Current perspectives for the treatment of chronic myeloid leukemia. Turk J Med Sci. 2019;49:1\u201310. https:\/\/doi.org\/10.3906\/sag-1810-81.","journal-title":"Turk J Med Sci"},{"key":"15843_CR31","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"J Sokal","year":"1984","unstructured":"Sokal J, Cox E, Baccarani M, Tura S, Gomez G, Robertson J, et al. Prognostic discrimination in good-risk chronic granulocytic leukemia. Blood. 1984;63:789\u201399.","journal-title":"Blood"},{"key":"15843_CR32","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41375-022-01527-y","volume":"36","author":"XS Zhang","year":"2022","unstructured":"Zhang XS, Gale RP, Zhang MJ, Huang XJ, Jiang Q. A predictive scoring system for therapy failure in persons with chronic myeloid leukemia receiving initial imatinib therapy. Leukemia. 2022;36:1336\u201342. https:\/\/doi.org\/10.1038\/s41375-022-01527-y.","journal-title":"Leukemia"},{"key":"15843_CR33","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","volume":"33","author":"M Baccarani","year":"2019","unstructured":"Baccarani M, Castagnetti F, Gugliotta G, Rosti G, Soverini S, Albeer A, et al. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia: an international overview. Leukemia. 2019;33:1173\u201383. https:\/\/doi.org\/10.1038\/s41375-018-0341-4.","journal-title":"Leukemia"},{"key":"15843_CR34","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.clml.2017.06.009","volume":"17","author":"KBB Pagnano","year":"2017","unstructured":"Pagnano KBB, Miranda EC, Delamain MT, Duarte GO, Paula EV, Lorand-Metze I, et al. Influence of BCR-ABL transcript type on outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. Clin Lymphoma Myeloma Leuk. 2017;17:728\u201333. https:\/\/doi.org\/10.1016\/j.clml.2017.06.009.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"15843_CR35","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1111\/cas.15501","volume":"113","author":"Y Su","year":"2022","unstructured":"Su Y, Kuo M, Chen T, Wang M, Yang Y, Ma M, et al. Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia. Cancer Sci. 2022;113:3518\u201327. https:\/\/doi.org\/10.1111\/cas.15501.","journal-title":"Cancer Sci"},{"key":"15843_CR36","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","volume":"127","author":"P Jain","year":"2016","unstructured":"Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Shamanna RK, et al. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. 2016;127:1269\u201375. https:\/\/doi.org\/10.1182\/blood-2015-10-674242.","journal-title":"Blood"},{"key":"15843_CR37","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.3324\/haematol.2019.240739","volume":"105","author":"S Branford","year":"2020","unstructured":"Branford S. Why is it critical to achieve a deep molecular response in chronic myeloid leukemia? Haematologica. 2020;105:2730\u20137. https:\/\/doi.org\/10.3324\/haematol.2019.240739.","journal-title":"Haematologica"},{"key":"15843_CR38","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa022457.","journal-title":"N Engl J Med"},{"key":"15843_CR39","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/ajh.24275","volume":"91","author":"E Jabbour","year":"2016","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016;91:252\u201365. https:\/\/doi.org\/10.1002\/ajh.24275.","journal-title":"Am J Hematol"},{"key":"15843_CR40","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384. https:\/\/doi.org\/10.1182\/blood-2013-05-501569.","journal-title":"Blood"},{"key":"15843_CR41","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.bjhh.2017.04.007","volume":"39","author":"AL Vieira-Mion","year":"2017","unstructured":"Vieira-Mion AL, Pereira NF, Funke VAM, Pasquini R. Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia. Rev Bras Hematol Hemoter. 2017;39:210\u20135. https:\/\/doi.org\/10.1016\/j.bjhh.2017.04.007.","journal-title":"Rev Bras Hematol Hemoter"},{"key":"15843_CR42","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41375-021-01260-y","volume":"35","author":"TP Hughes","year":"2021","unstructured":"Hughes TP, Clementino NCD, Fominykh M, Lipton JH, Turkina AG, Moiraghi EB, et al. Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update. Leukemia. 2021;35:1631\u201342. https:\/\/doi.org\/10.1038\/s41375-021-01260-y.","journal-title":"Leukemia"},{"key":"15843_CR43","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1038\/s41375-023-02028-2","volume":"37","author":"M Lauseker","year":"2023","unstructured":"Lauseker M, Hehlmann R, Hochhaus A, Saussele S. Survival with chronic myeloid leukaemia after failing milestones. Leukemia. 2023;37:2231\u20136. https:\/\/doi.org\/10.1038\/s41375-023-02028-2.","journal-title":"Leukemia"},{"key":"15843_CR44","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","volume":"123","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123:1353\u201360. https:\/\/doi.org\/10.1182\/blood-2013-06-510396.","journal-title":"Blood"},{"key":"15843_CR45","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531\u201341. https:\/\/doi.org\/10.1056\/NEJMoa055229.","journal-title":"N Engl J Med"},{"key":"15843_CR46","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5-year study results of DASISION: dasatinib versus imatinib in treatment-naive chronic myeloid leukemia. J Clin Oncol. 2016;34:2333\u201340. https:\/\/doi.org\/10.1200\/JCO.2015.64.8899.","journal-title":"J Clin Oncol"},{"key":"15843_CR47","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia: ENESTnd 10-year analysis. Leukemia. 2021;35:440\u201353. https:\/\/doi.org\/10.1038\/s41375-020-01111-2.","journal-title":"Leukemia"},{"key":"15843_CR48","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia. J Clin Oncol. 2010;28:2381\u20138. https:\/\/doi.org\/10.1200\/JCO.2009.26.3087.","journal-title":"J Clin Oncol"},{"key":"15843_CR49","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.3390\/jcm9113671","volume":"9","author":"R Hehlmann","year":"2020","unstructured":"Hehlmann R. The new ELN recommendations for treating CML. J Clin Med. 2020;9:3671. https:\/\/doi.org\/10.3390\/jcm9113671.","journal-title":"J Clin Med"},{"key":"15843_CR50","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1038\/s41375-020-0805-1","volume":"34","author":"JE Cortes","year":"2020","unstructured":"Cortes JE, Jiang Q, Wang J, Weng J, Zhu H, Liu X, et al. Dasatinib versus imatinib in patients with chronic myeloid leukemia who have not achieved an optimal response after 3 months of imatinib: DASCERN study. Leukemia. 2020;34:2064\u201373. https:\/\/doi.org\/10.1038\/s41375-020-0805-1.","journal-title":"Leukemia"},{"key":"15843_CR51","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1182\/blood-2013-12-544015","volume":"124","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, Lipton JH, Spector N, Cervantes F, Pasquini R, Clementino NCD, et al. Deep molecular responses in patients with CML switched to nilotinib after long-term imatinib. Blood. 2014;124:729\u201336. https:\/\/doi.org\/10.1182\/blood-2013-12-544015.","journal-title":"Blood"},{"key":"15843_CR52","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","volume":"61","author":"NP Shah","year":"2020","unstructured":"Shah NP, Garcia-Gutierrez V, Jimenez-Velasco A, Larson S, Saussele S, Rea D, et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: DASFREE study. Leuk Lymphoma. 2020;61:650\u20139. https:\/\/doi.org\/10.1080\/10428194.2019.1675879.","journal-title":"Leuk Lymphoma"},{"key":"15843_CR53","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1200\/JCO.23.01647","volume":"42","author":"FX Mahon","year":"2024","unstructured":"Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, et al. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI): final analysis and prognostic factors for treatment-free remission. J Clin Oncol. 2024;42:1875\u201380. https:\/\/doi.org\/10.1200\/JCO.23.01647.","journal-title":"J Clin Oncol"},{"key":"15843_CR54","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: TWISTER study. Blood. 2013;122:515\u201322. https:\/\/doi.org\/10.1182\/blood-2013-02-483750.","journal-title":"Blood"},{"key":"15843_CR55","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.5045\/br.2023.2023035","volume":"58","author":"JJ Han","year":"2023","unstructured":"Han JJ. Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia. Blood Res. 2023;58:S58\u201365. https:\/\/doi.org\/10.5045\/br.2023.2023035.","journal-title":"Blood Res"},{"key":"15843_CR56","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-024-00935-1","volume":"14","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian H, Cortes JE. Chronic myeloid leukemia: current state of the art and future perspectives. Blood Cancer J. 2024;14:32. https:\/\/doi.org\/10.1038\/s41408-024-00935-1.","journal-title":"Blood Cancer J"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15843-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15843-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15843-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:48:13Z","timestamp":1781642893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15843-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15843"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15843-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8263850\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical principles of the Declaration of Helsinki. The study protocol was approved by the Research Ethics Committee of the Funda\u00e7\u00e3o Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM) under approval number 4.632.515. All participants provided written informed consent prior to inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"556"}}